hydroxocobalamin acetate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4644 22465-48-1

Description:

MoleculeDescription

Synonyms:

  • hydroxocobalamin acetate
  • acetatocobalamin
  • hydroxycobalamine acetate
  • Molecular weight: 1388.41
  • Formula: C64H91CoN13O16P
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 515.01
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 115.77 24.09 75 3113 108532 53237346
Forceps delivery 44.36 24.09 8 3180 185 53345693
Lethargy 42.61 24.09 31 3157 53729 53292149
Neutropenic sepsis 40.40 24.09 19 3169 14630 53331248
Food refusal 40.27 24.09 8 3180 314 53345564
Nystagmus 37.61 24.09 14 3174 6022 53339856
Pneumonia aspiration 34.73 24.09 23 3165 34278 53311600
Acute kidney injury 33.90 24.09 57 3131 253811 53092067
Developmental hip dysplasia 33.66 24.09 9 3179 1321 53344557
Somnolence 32.80 24.09 45 3143 167689 53178189
Inappropriate antidiuretic hormone secretion 31.09 24.09 16 3172 14935 53330943
Haemorrhage in pregnancy 30.94 24.09 9 3179 1796 53344082
Pelvic deformity 30.14 24.09 6 3182 238 53345640
Coma scale abnormal 28.61 24.09 11 3177 5167 53340711
Drug ineffective 26.63 24.09 8 3180 817237 52528641
Medication error 24.42 24.09 19 3169 36346 53309532
Swelling face 24.34 24.09 23 3165 57145 53288733

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Loss of proprioception 34.55 25.54 7 2238 262 32511019
Acute kidney injury 33.88 25.54 67 2178 293401 32217880
Orthostatic hypotension 32.79 25.54 21 2224 25629 32485652
Confusional state 30.36 25.54 43 2202 143072 32368209
Hypomania 27.10 25.54 9 2236 2400 32508881

Pharmacologic Action:

SourceCodeDescription
FDA EPC N0000175429 Antidote
MeSH PA D006397 Hematinics
MeSH PA D006401 Hematologic Agents
MeSH PA D018977 Micronutrients
MeSH PA D014803 Vitamin B Complex
MeSH PA D014815 Vitamins
CHEBI has role CHEBI:75835 antianemia drug

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D02707 KEGG_DRUG
4017962 VUID
N0000146312 NUI
4017961 VANDF
4017962 VANDF
CHEBI:27786 CHEBI
I2A PDB_CHEM_ID
CHEMBL2103737 ChEMBL_ID
1043 INN_ID
S535M27N3Q UNII
91663261 PUBCHEM_CID
44475014 PUBCHEM_CID
DB00200 DRUGBANK_ID
236302 RXNORM
4850 MMSL
7093 MMSL
d03133 MMSL
001044 NDDF
005609 NDDF
327529002 SNOMEDCT_US
409258004 SNOMEDCT_US
734651006 SNOMEDCT_US
D006879 MESH_DESCRIPTOR_UI
C0771561 UMLSCUI
C0020316 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Hydroxocobalamin HUMAN PRESCRIPTION DRUG LABEL 1 0591-2888 INJECTION, SOLUTION 1000 ug INTRAMUSCULAR ANDA 16 sections
Hydroxocobalamin HUMAN PRESCRIPTION DRUG LABEL 1 50090-3548 INJECTION, SOLUTION 1000 ug INTRAMUSCULAR ANDA 16 sections
ARONAMIN GOLD HUMAN OTC DRUG LABEL 5 72689-0024 TABLET, FILM COATED 5.22 ug ORAL unapproved drug other 7 sections